Skip to main content

eflornithine

Generic: CPP-1X·Brand: IWILFIN, Iwilfin, ORNIDYL, VANIQA·Code: CPP-1X, CPP-1X-S, CPP-1X-T

eflornithine: sourced relationships with 1 company · 5 clinical trials tracked.

eflornithine evidence translation

What we can confirm

What it means

Source-backed records connect eflornithine to SNBP; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could eflornithine → SNBP affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence7 indications · 0 study sponsors

Related indications

Gastric cancer, Type 1 diabetes, metastatic castration-resistant prostate cancer, NSCLC (STK11 mutation)Diffuse Intrinsic Pontine GliomaEwing SarcomaMedulloblastomaNeuroblastomaOsteosarcomaProstate Cancer

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
PANBELA THERAPEUTICS, INC. (SNBP)
developer · Reported 2024-03-26 · Current development: unknownSource
Gastric cancer, Type 1 diabetes, metastatic castration-resis…
Phase 2
Clinical Trial Registry Records (5)

An Intermediate Expanded Use Trial of DFMO

NCT03581240Registry updated 2026-02-20·N/A
Available
Expanded Access1 site · United StatesGiselle Sholler

A Phase II Open Label Basket Trial Study Using Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

NCT07321912Registry updated 2026-06-12·Phase 2
Recruiting

Primary endpoint: Number of Cohort 1 participants with relapse free survival (RFS) during study

Interventionalopen406 targetStarted 2026-06Completion 2036-062 sites · United StatesMilton S. Hershey Medical Center

A Phase I/II Study Using Eflornithine (DFMO) and AMXT 1501 for Relapsed and Refractory Neuroblastoma, CNS Tumors, and Sarcomas

NCT06465199Registry updated 2026-06-18·Phase 1/Phase 2
Recruiting

Primary endpoint: Phase I- Number of Participants with Adverse Events as a Measure of Safety and Tolerability

InterventionalRandomizedopen289 targetStarted 2026-05Completion 2035-0511 sites · United StatesMilton S. Hershey Medical Center

Repeat Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Asymptomatic Patients With Metastatic Castration-Resistant Prostate Cancer: The APEX (Androgen and Polyamine Elimination Alternating With Xtandi) Trial

NCT06059118Registry updated 2026-01-14·Phase 2
Recruiting

Primary endpoint: PSA response rate at Cycle 1 Day 64

Interventionalopen50 targetStarted 2023-10Completion 2029-111 site · United StatesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma

NCT02559778Registry updated 2026-02-20·Phase 2
Recruiting

Primary endpoint: Number of days from start of therapy to date of first relapse

InterventionalRandomizedopen500 targetStarted 2015-09Completion 2035-0927 sites · Canada, United StatesGiselle Sholler

Frequently asked questions

Which companies have sourced relationships with eflornithine?

eflornithine has dated SEC/FDA relationship records for PANBELA THERAPEUTICS, INC..

How many clinical trials involve eflornithine?

BioSniper tracks 5 clinical trials involving eflornithine.